Display options
Share it on

Endocr Pathol. 2000;11(2):137-143. doi: 10.1385/ep:11:2:137.

Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression.

Endocrine pathology

Celina G. Kleer, Bonita R. Bryant, Thomas J. Giordano, Mark Sobel, Maria J. Merino

Affiliations

  1. MT (ASCP).

PMID: 12114819 DOI: 10.1385/ep:11:2:137

Abstract

Little is known about the genetic alterations that occur during the progression of thyroid neoplasms. To understand better the biology of thyroid tumors, we investigated several genetic loci in benign and malignant thyroid neoplasms. Forty-one thyroid tumors (6 adenomas, 16 papillary, 14 follicular, and 5 anaplastic carcinomas) were studied. Normal and tumor cells were microdissected from paraffin-embedded tissues. DNA was used for polymerase chain reaction-based loss of heterozygosity (LOH) analysis with the following markers: D1S243 (1p35-36), D1S165 (1p36) and D1S162 (1p32), TP53 (17p13), and INT-2 (11q13). Immunohistochemistry for Ki-67 was performed. The Ki-67 labeling index (LI) was the percentage of positive tumor cells. LOH at 1p was seen in 2 of 5 (40%) informative cases of anaplastic carcinoma (2 of 2 at D1S162 and 1 of 2 at D1S165) and in 2 of 11 (18%) informative cases of follicular carcinoma (2 of 7 at D1S243, 2 of 7 at D1S1654, and 1 of 6 at D1S162). One anaplastic (20%) and two follicular carcinomas (14%) had LOH in at least two of the 1p loci analyzed. None of the adenomas and papillary carcinomas had LOH at these loci. LOH at 17p and 11q13 were infrequent. Ki-67 LI was 1.4, 7, 16, and 65% in adenomas, papillary, follicular, and anaplastic carcinomas, respectively. Allelic loss at 1p may occur in aggressive types of thyroid carcinoma and may be a marker of poor prognosis. LOH at 1p may represent a late genetic event in thyroid carcinogenesis. LOH at 17p and 11q13 (MEN gene locus) is uncommon in thyroid neoplasms.

References

  1. Nature. 1987 Jul 9-15;328(6126):170-2 - PubMed
  2. J Clin Invest. 1992 May;89(5):1517-22 - PubMed
  3. J Clin Endocrinol Metab. 1997 Nov;82(11):3684-91 - PubMed
  4. Oncogene. 1995 Mar 16;10(6):1095-101 - PubMed
  5. Jpn J Cancer Res. 1992 Dec;83(12):1293-8 - PubMed
  6. Oncogene. 1992 Jul;7(7):1331-7 - PubMed
  7. N Engl J Med. 1993 Oct 28;329(18):1318-27 - PubMed
  8. Cancer Res. 1990 Nov 15;50(22):7232-5 - PubMed
  9. Oncogene. 1989 Dec;4(12):1457-62 - PubMed
  10. Cancer Res. 1992 Mar 1;52(5):1369-71 - PubMed
  11. Am J Surg Pathol. 1993 Apr;17(4):375-81 - PubMed
  12. Oncogene. 1990 Apr;5(4):565-70 - PubMed
  13. Crit Rev Oncog. 1995;6(1):35-46 - PubMed
  14. Eur J Endocrinol. 1996 Feb;134(2):177-83 - PubMed
  15. Eur J Endocrinol. 1995 Nov;133(5):513-22 - PubMed
  16. J Clin Invest. 1993 Jan;91(1):179-84 - PubMed
  17. Br J Urol. 1993 Nov;72(5 Pt 2):736-9 - PubMed
  18. Am J Surg Pathol. 1994 Oct;18(10):1054-64 - PubMed
  19. Br Med Bull. 1994 Jul;50(3):582-99 - PubMed
  20. J Clin Endocrinol Metab. 1990 Jul;71(1):223-9 - PubMed
  21. Cancer Res. 1993 Apr 15;53(8):1895-8 - PubMed
  22. Am J Pathol. 1995 Mar;146(3):620-5 - PubMed
  23. Cell. 1990 Feb 23;60(4):557-63 - PubMed
  24. Am J Clin Pathol. 1995 Sep;104(3):313-8 - PubMed
  25. J Lab Clin Med. 1994 Mar;123(3):331-7 - PubMed
  26. Mol Endocrinol. 1990 Oct;4(10):1474-9 - PubMed
  27. Oncogene. 1995 Jan 19;10(2):291-7 - PubMed

Publication Types